AR078797A1 - Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc - Google Patents
Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del sncInfo
- Publication number
- AR078797A1 AR078797A1 ARP100103948A ARP100103948A AR078797A1 AR 078797 A1 AR078797 A1 AR 078797A1 AR P100103948 A ARP100103948 A AR P100103948A AR P100103948 A ARP100103948 A AR P100103948A AR 078797 A1 AR078797 A1 AR 078797A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- pharmaceutical compositions
- caseina
- quinasa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Se dan a conocer también las composiciones farmacéuticas, los procedimientos de tratamiento, los procedimientos de síntesis y los productos intermedios correspondiente Reivindicacion 1: Un compuesto de formula (1): o sus sales farmacéuticamente aceptables caracterizado porque: A es un heterocicloalquilo de 4 a 7 miembros que contiene nitrogeno o, alternativamente, A se puede condensar directamente con el anillo al cual está unido mediante R1; L es alquilo C1-3; R1 es hidrogeno, alquilo C1-3 o cicloalquilo C3-4; cada R2 es independientemente alquilo C1-3, fluor, hidroxilo, alcoxi C1-3 o ciano; R3 es hidrogeno, alquilo C1-3 o cicloalquilo C3-4; R4 es un heteroarilo de 5 a 10 miembros con de 1 a 3 heteroátomos, sustituido opcionalmente con de uno a tres sustituyentes R7; R5 es hidrogeno o -N(R8)2; R6 es hidrogeno, halogeno o alquilo C1-3; cada R7 es independientemente halogeno, (CH2)t-Fq, alquilo C1-3, -CF3, -(CH2)t-cicloalquilo C3-4, -(CH2)t-O-alquilo C1-3, -(CH2)t-ciano o -(CH2)t-hidroxi; Z es N o CR9; cada R8 es independientemente hidrogeno o alquilo C1-3; R9 es hidrogeno, alquilo C1-3 o halogeno; m es 0, 1 o 2; n es 0, 1 o 2; q es 1, 2 o 3; t es 0, 1 o 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25550609P | 2009-10-28 | 2009-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078797A1 true AR078797A1 (es) | 2011-12-07 |
Family
ID=43301770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103948A AR078797A1 (es) | 2009-10-28 | 2010-10-28 | Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8518944B2 (es) |
| EP (1) | EP2493876B1 (es) |
| JP (1) | JP5784620B2 (es) |
| KR (1) | KR101421852B1 (es) |
| CN (1) | CN102686580B (es) |
| AR (1) | AR078797A1 (es) |
| AU (1) | AU2010311035B2 (es) |
| CA (1) | CA2777632C (es) |
| DK (1) | DK2493876T3 (es) |
| ES (1) | ES2460065T3 (es) |
| HK (1) | HK1171220A1 (es) |
| HR (1) | HRP20140252T1 (es) |
| IL (1) | IL219190A0 (es) |
| IN (1) | IN2012DN03182A (es) |
| MX (1) | MX2012004997A (es) |
| PL (1) | PL2493876T3 (es) |
| PT (1) | PT2493876E (es) |
| RS (1) | RS53246B (es) |
| SI (1) | SI2493876T1 (es) |
| TW (1) | TW201125864A (es) |
| UY (1) | UY32977A (es) |
| WO (1) | WO2011051858A1 (es) |
| ZA (1) | ZA201202776B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007334260A1 (en) | 2006-11-15 | 2008-06-26 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| CN103260622B (zh) | 2010-12-20 | 2015-05-13 | 辉瑞大药厂 | 作为酪蛋白激酶抑制剂的新型稠合吡啶化合物 |
| EP2935271B1 (en) | 2012-12-21 | 2017-10-25 | Bristol-Myers Squibb Company | Novel substituted imidazoles as casein kinase 1 / inhibitors |
| US9732065B2 (en) | 2013-05-30 | 2017-08-15 | Sumitomo Dainippon Pharma Co., Ltd. | Cyclic aminomethyl pyrimidine derivative |
| ES2926931T3 (es) | 2014-02-07 | 2022-10-31 | Agency Science Tech & Res | Inhibidores de caseína quinasa 1 basados en azoles 2,4,5-tri-sustituidos como inductores de la cardiomiogénesis |
| WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| US10722513B2 (en) | 2015-03-23 | 2020-07-28 | The University Of Melbourne | Treatment of respiratory diseases |
| US11185536B2 (en) * | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| EP3943090A1 (en) | 2016-01-29 | 2022-01-26 | Massachusetts Eye & Ear Infirmary | Expansion and differentiation of inner ear supporting cells and methods of use thereof |
| CN110753688A (zh) * | 2017-05-03 | 2020-02-04 | 墨尔本大学 | 用于治疗呼吸***疾病的化合物 |
| US10973820B2 (en) | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| JP2022500493A (ja) * | 2018-09-09 | 2022-01-04 | カナートファーマ アーゲー | 血管疾患の治療におけるカゼインキナーゼ１阻害剤の使用 |
| US20220002269A1 (en) * | 2018-11-07 | 2022-01-06 | The University Of Melbourne | Novel compounds for the treatment of respiratory diseases |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| CN115335057A (zh) * | 2020-03-27 | 2022-11-11 | 北京原基华毅生物科技有限公司 | 抑制酪蛋白激酶的方法 |
| CN115298183A (zh) * | 2020-03-27 | 2022-11-04 | 北京原基华毅生物科技有限公司 | 作为酪蛋白激酶抑制剂的化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06502178A (ja) * | 1990-12-31 | 1994-03-10 | 藤沢薬品工業株式会社 | イミダゾトリアジン誘導体 |
| IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| JP2000507558A (ja) * | 1996-03-25 | 2000-06-20 | スミスクライン・ビーチャム・コーポレイション | Ｃｎｓ損傷についての新規な治療 |
| US6239279B1 (en) | 1998-12-16 | 2001-05-29 | Smithkline Beecham Corporation | Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives |
| GB0108770D0 (en) * | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
| JP2004536597A (ja) * | 2001-06-18 | 2004-12-09 | ザ ロックフェラー ユニバーシティー | 代謝共役型グルタミン酸受容体シグナル伝達経路を介する神経機能の調節 |
| AU2004303826A1 (en) * | 2003-12-11 | 2005-07-07 | Aventis Pharmaceuticals Inc. | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase I Epsilon |
| JO2629B1 (en) * | 2004-08-19 | 2012-06-24 | افينتيس فارما سوتيكالز انك | Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon |
| DE602005017162D1 (de) * | 2004-08-19 | 2009-11-26 | Aventis Pharma Inc | 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i |
| WO2007048065A2 (en) * | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Pyrimidinones as casein kinase ii (ck2) modulators |
| EP2308866A1 (de) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
| CN103260622B (zh) | 2010-12-20 | 2015-05-13 | 辉瑞大药厂 | 作为酪蛋白激酶抑制剂的新型稠合吡啶化合物 |
-
2010
- 2010-10-20 WO PCT/IB2010/054749 patent/WO2011051858A1/en active Application Filing
- 2010-10-20 SI SI201030539T patent/SI2493876T1/sl unknown
- 2010-10-20 AU AU2010311035A patent/AU2010311035B2/en not_active Ceased
- 2010-10-20 JP JP2012535977A patent/JP5784620B2/ja active Active
- 2010-10-20 DK DK10774282.7T patent/DK2493876T3/en active
- 2010-10-20 ES ES10774282.7T patent/ES2460065T3/es active Active
- 2010-10-20 KR KR1020127013537A patent/KR101421852B1/ko not_active IP Right Cessation
- 2010-10-20 CA CA2777632A patent/CA2777632C/en not_active Expired - Fee Related
- 2010-10-20 RS RS20140157A patent/RS53246B/en unknown
- 2010-10-20 EP EP10774282.7A patent/EP2493876B1/en active Active
- 2010-10-20 PL PL10774282T patent/PL2493876T3/pl unknown
- 2010-10-20 PT PT107742827T patent/PT2493876E/pt unknown
- 2010-10-20 CN CN201080059759.7A patent/CN102686580B/zh not_active Expired - Fee Related
- 2010-10-20 MX MX2012004997A patent/MX2012004997A/es active IP Right Grant
- 2010-10-20 IN IN3182DEN2012 patent/IN2012DN03182A/en unknown
- 2010-10-25 US US12/911,030 patent/US8518944B2/en active Active
- 2010-10-25 TW TW099136328A patent/TW201125864A/zh unknown
- 2010-10-27 UY UY0001032977A patent/UY32977A/es not_active Application Discontinuation
- 2010-10-28 AR ARP100103948A patent/AR078797A1/es not_active Application Discontinuation
-
2012
- 2012-04-15 IL IL219190A patent/IL219190A0/en unknown
- 2012-04-16 ZA ZA2012/02776A patent/ZA201202776B/en unknown
- 2012-11-21 HK HK12111895.9A patent/HK1171220A1/xx not_active IP Right Cessation
-
2014
- 2014-03-18 HR HRP20140252AT patent/HRP20140252T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012004997A (es) | 2012-06-12 |
| CA2777632C (en) | 2014-02-25 |
| AU2010311035B2 (en) | 2013-05-16 |
| CN102686580B (zh) | 2014-09-10 |
| EP2493876A1 (en) | 2012-09-05 |
| CN102686580A (zh) | 2012-09-19 |
| HK1171220A1 (en) | 2013-03-22 |
| PT2493876E (pt) | 2014-03-20 |
| WO2011051858A1 (en) | 2011-05-05 |
| ES2460065T3 (es) | 2014-05-13 |
| RS53246B (en) | 2014-08-29 |
| KR20120088759A (ko) | 2012-08-08 |
| PL2493876T3 (pl) | 2014-06-30 |
| EP2493876B1 (en) | 2014-02-12 |
| DK2493876T3 (en) | 2014-03-10 |
| IN2012DN03182A (es) | 2015-09-25 |
| CA2777632A1 (en) | 2011-05-05 |
| KR101421852B1 (ko) | 2014-07-22 |
| US20110098272A1 (en) | 2011-04-28 |
| IL219190A0 (en) | 2012-06-28 |
| HRP20140252T1 (hr) | 2014-04-25 |
| JP5784620B2 (ja) | 2015-09-24 |
| ZA201202776B (en) | 2013-06-26 |
| TW201125864A (en) | 2011-08-01 |
| UY32977A (es) | 2011-05-31 |
| SI2493876T1 (sl) | 2014-04-30 |
| US8518944B2 (en) | 2013-08-27 |
| JP2013509392A (ja) | 2013-03-14 |
| AU2010311035A1 (en) | 2012-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078797A1 (es) | Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc | |
| AR079260A1 (es) | Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR065322A1 (es) | 2-aminooxazolinas comoligandos de taar1 | |
| ES2655391T3 (es) | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
| AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR067444A1 (es) | Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas | |
| AR075510A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR073136A1 (es) | Compuestos de pirrol | |
| AR079636A1 (es) | Antagonistas del receptor ccr2 y usos de los mismos | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR063601A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| CO5650164A2 (es) | Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
| AR082889A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| CO6140030A2 (es) | Derivados de 4-bencilftalazinona 2-sustituidos como antagonistas de histamina h1 y h3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |